![](https://cdn.sanity.io/images/0vv8moc6/contagion/e1ffc2a1d146f0707f92e284b39a9593753e4a35-400x400.jpg?fit=crop&auto=format)
The Future of Influenza Vaccination: Insights from FluGen’s M2SR Vaccine Study
A recent study published in The Lancet assessed the safety, tolerability, and immunological response to FluGen’s investigational supra-seasonal, live, single-replication intranasal influenza vaccine (M2SR) when administered alongside Sanofi’s Fluzone High- …